Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV.
Alessandra VergoriAlessandro Cozzi LepriStefania CicaliniGiulia MatusaliVeronica BordoniSimone LaniniSilvia MeschiRoberta IannazzoValentina MazzottaFrancesca ColavitaIlaria MastrorosaEleonora CiminiDavide MariottiLydia De PascaleAlessandra MaraniPaola GallìAnnaRosa GarbugliaConcetta CastillettiVincenzo PuroChiara AgratiEnrico GirardiFrancesco VaiaAndrea Antinorinull nullPublished in: Nature communications (2022)
In order to investigate safety and immunogenicity of SARS-CoV-2 vaccine third dose in people living with HIV (PLWH), we analyze anti-RBD, microneutralization assay and IFN-γ production in 216 PLWH on ART with advanced disease (CD4 count <200 cell/mm 3 and/or previous AIDS) receiving the third dose of a mRNA vaccine (BNT162b2 or mRNA-1273) after a median of 142 days from the second dose. Median age is 54 years, median CD4 nadir 45 cell/mm 3 (20-122), 93% HIV-RNA < 50 c/mL. In 68% of PLWH at least one side-effect, generally mild, is recorded. Humoral response after the third dose was strong and higher than that achieved with the second dose (>2 log 2 difference), especially when a heterologous combination with mRNA-1273 as third shot is used. In contrast, cell-mediated immunity remain stable. Our data support usefulness of third dose in PLWH currently receiving suppressive ART who presented with severe immune dysregulation.
Keyphrases
- sars cov
- antiretroviral therapy
- single cell
- hiv infected
- cell therapy
- immune response
- coronavirus disease
- magnetic resonance
- stem cells
- high throughput
- magnetic resonance imaging
- hepatitis c virus
- electronic health record
- hiv aids
- early onset
- respiratory syndrome coronavirus
- dendritic cells
- south africa
- contrast enhanced
- data analysis